May 19, 2008

Quigley Corp announces success with infectious bronchitis drug

The Quigley Corp. has announced positive results from a study conducted in chickens to evaluate the anti-viral activity of its compound QR448(a).

The compound was administered to chicks that had been infected with Infectious Bronchitis Virus (IBV). Data indicates that QR448(a) is efficacious against an IBV challenge in 2-week-old specific pathogen-free (SPF) chicks.

Infectious bronchitis caused by IBV may result in lowered weight gains, poor production, low egg quality, and in severe cases, mortality.

The Company began the study after receiving feedback from poultry industry leaders who expressed an increasing need for additional products to combat IBV.

Richard Rosenbloom, executive vice president and COO of Quigley Pharm said the  non-vaccine, broad spectrum antiviral has the potential to offer the poultry industry a natural base solution to the growing problem.